Mucopolysaccharidosis Type VI

DBCOND0063468Congenital, Hereditary, and Neonatal Diseases and AbnormalitiesNutritional and Metabolic Diseases

Mucopolysaccharidosis Type VI is the indication for 1 drug in DrugBank. It is covered by 1 curated, structured indication.

Also known as
Mucopolysaccharidosis VI · Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy Syndrome) · Maroteaux-Lamy Syndrome · MPS VI · Maroteaux-lamy Disease
Classified under
Indicated drugs

Resolves to

Vocabularies
MeSHM0014176SNOMED CT52677002MedDRA10056892UMLSC0026709

What you can answer from here — as of October 23, 2026

1Indicated drugWith each drug's targets and mechanism
Listed above
1Structured indicationPopulation, line of therapy, route and combination as fields, not prose
Sign in
20Clinical trialsPhase, status and sponsor resolved per trial
Sign in

Which approved drugs for Mucopolysaccharidosis Type VI share a target, and which companies have late-stage candidates against it?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In